Progression of diabetic nephropathy in normotensive type 1 rate (GFR): 0 to 24 ml/min/year, mean 12 to 15 ml/min/ diabetic patients.
GFR and the prognosis of diabetic nephropathy [5] [6] [7] [8] [9] . tion, since as many as 25% of type 1 diabetic patients 19; 113 Ϯ 22 ml/min/1.73 m 2 , respectively; mean Ϯ sd), arterial with this complication are normotensive [6, 10] . blood pressure, albuminuria, and hemoglobin A 1c . During the The aim of our long-term observational follow-up follow-up there was a median rate of decline in GFR in all 59 patients of 1.2 (range 12.9 to -4.4) ml/min/year. During the study was to describe the natural history of diabetic nestudy period no significant differences were observed in: the phropathy in normotensive type 1 diabetic patients. Furrate of decline in glomerular filtration rate [median (range) thermore, we evaluated genetic and nongenetic progres-0.9 (10.6 to -1.9); 2.5 (12.9 to -4.4); 1.4 (10.8 to -1.9 ml/min/ sion promoters.
year)], arterial blood pressure, albuminuria, hemoglobin A 1c or cholesterol between the three groups (II, ID and DD), respectively. At baseline, multiple linear regression analysis METHODS including the above-mentioned putative risk factors revealed that albuminuria, short stature, and male gender independently Patients predict an enhanced decline in GFR [R 2 (adjusted) ϭ 0.33;
We examined the records of all adult Caucasian type P Ͻ 0.002]. During the follow-up period, only albuminuria acted 1 diabetic patients with persistent albuminuria (Ͼ200 as an independent progression promoter [R 2 (adjusted) ϭ 0.37; P Ͻ 0.0001].
g/min in 2 out of 3 consecutive determinations carried
Conclusions. Our study revealed a rather slow progression out within a 6-month period) attending the outpatient of kidney disease in normotensive type 1 diabetic patients with clinic at Steno Diabetes Center between 1993 and 1996 diabetic nephropathy. Albuminuria, short stature, and male who had diabetic nephropathy and who had their GFR gender act as progression promoters in such patients. measured during the same period. Diabetic nephropathy was diagnosed clinically if there were persistent albuminuria, diabetic retinopathy, diabetes duration of more Studies of the natural history of diabetic nephropathy than 10 years and absence of any clinical or laboratory have been carried out in small numbers of mainly hyperevidence of other kidney or renal tract disease [11] . Patensive (diastolic BP Ͼ 90 mm Hg) patients, revealing tients fulfillling the following criteria could be enrolled: a large variation in the decrease in glomerular filtration diabetic nephropathy, normotension, no renoprotective therapies including angiotensin converting enzyme (ACE) inhibitors, at least three GFR measurements dur- filled these criteria and all gave fully informed consent. were measured enzymatically using CHOD-PAP reagens from Boehringer-Mannheim GmbH (Mannheim, In our clinic, GFR is measured routinely approximately once a year from onset of diabetic nephropathy in all Germany). Genotyping was performed as described in detail previously [14] and subjects were classified ac-type 1 diabetic patients. Baseline data are based on values from the year of the first GFR measurement (Table  cording to the presence (I) or absence (D) of a 287 base pair insertion in intron 16 of the ACE-gene into II, ID 1). Median time from onset of diabetic nephropathy to first GFR determination was one year (range 0.1 to 9 or DD genotypes. Diabetic retinopathy was assessed by fundus photography after pupillary dilation. Patients years). Arterial hypertension was diagnosed according to WHO criteria, and antihypertensive medication pre-were on a diabetic diet (45 to 55% carbohydrates, 30 to 35% fat, and 15 to 20% protein) without restriction in scribed if at least three consecutive recordings revealed a systolic BP Ͼ160 mm Hg and/or a diastolic BP Ͼ95 sodium or protein intake. mm Hg. The experimental design was approved by the Statistical analysis local ethical committee.
Values are given as means (sd), except for urinary Methods albumin concentration and serum creatinine, which are expressed as geometric means with 95% confidence in-Glomerular filtration rate and other physiological investigations were carried out 3 to 24 (median 7) times terval (CI) owing to the skewed distribution. Other nonnormally distributed variables are given as medians during 2.2 to 18.3 (5.5) years (NS between ACE/ID groups). The GFR was measured applying a single intra-(range). Linear regression analysis was used to assess the rate of decline in GFR from all values obtained without venous injection of 51 Cr-EDTA (3.7 MBq) and thereafter following the plasma clearance of the tracer for four antihypertensive treatment. Calculations of baseline blood pressure, urinary albumin excretion rate and HbA 1C are hours [12] . The mean day to day coefficient of variation in GFR in individuals is 4% in our laboratory. At baseline a multiple linear regression analysis of putative risk factors revealed that albuminuria, short stature and male gender independently predict an accelerated rate of decline in GFR (R 2 ϭ 0.33; P Ͻ 0.002), whereas ACE/ID genotype, BP, HbA 1C , serum choles- during the follow-up period was albuminuria [R 2 (adjusted) ϭ 0.37; P Ͻ 0.0001]. Patients with albuminuria in the lowest tertiles had rate of decline in GFR of only [median (range)] 0.2 (10.6 to -4.4) ml/min/year, whereas encing the rate of decline in GFR were performed with the rate of decline was 3.0 (12.9 to -0.8) ml/min/year in backward selection. The following putative progression those patients with albuminuria in the highest tertiles promoters were included in the analyses: ACE/ID geno-(P Ͻ 0.01; Table 3 ). It should be mentioned that HbA 1c type, BP, albuminuria, HbA 1c , cholesterol, smoking, was nearly identical in the three groups. height and gender. The two latter variables were excluded in the analysis during the follow-up period. ACE/ ID genotype was entered as an ordered categorical vari-DISCUSSION able (II ϭ 1, ID ϭ 2, DD ϭ 3) due to the relationship Our six-year observational follow-up study of normobetween genotype and serum ACE levels. The R 2 value tensive type 1 diabetic patients with diabetic nephropais adjusted for the number of levels introduced into the thy revealed a median loss in GFR of Ϸ1 ml/min/year, model. A P-value (two sided) of Ͻ 0.05 was considered a GFR reduction equal to that observed with the natural to be significant. All calculations were performed using aging process. Increased baseline albuminuria, short stat-SPSS (SPSS, Chicago, IL, USA). ure and male gender predicted a steeper rate of decline in GFR, while albuminuria was the only independent RESULTS progression promoter during the follow-up period.
To obtain a valid determination of the rate of decline At baseline the patient groups with different genoin GFR in individual patients with chronic progressive types were similar with regard to all recorded variables kidney disease, the following requirements should be (Table 1) .
fulfilled: the applied GFR method should have a good During follow-up we demonstrated a rate of decline accuracy and precision, repeated GFR determination in GFR in all 59 patients of [median (range)] 1. 2 (12.9 should be performed, and the observation period should to Ϫ4.4) ml/min/year (Fig. 1) . No significant difference be extended to at least two years [15] . These requirein the rate of decline in the GFR between the groups ments were fulfilled in our study. with different ACE/ID genotypes (II, ID, DD) was ob-
In agreement with previous studies of the natural hisserved (ml/min/year): 0.9 (10.6 to -1.9); 2.5 (12.9 to Ϫ4.4) tory of diabetic nephropathy in mainly hypertensive type and 1.4 (10.8 to Ϫ1.9), respectively. The nongenetic pro-1 diabetic patients [1-3, 16], we found a considerable gression promoters BP, albuminuria, HbA 1C and serum variation in the rate of decline in GFR in our normotencholesterol concentration were similar in the three sive patient group. In an attempt to explain this variation groups during the whole follow-up of the study ( Table 2) .
we investigated some genetic and several nongenetic risk Thirty-one of the patients (53%) developed hypertenfactors, so-called progression promoters. sion and therefore had their observation period termi-Recently, we have shown that hypertensive type 1 nated. The time from onset of diabetic nephropathy to diabetic patients treated with an ACE inhibitor have a antihypertensive medications were prescribed was [merate of decline in GFR of 5.7 ml/min/year if they are dian (range)] 7 (3 to 14) years.
homozygous for the D allele as compared to 2.6 ml/min/ The 31 patients who later developed hypertension had year in patients having the ID or II genotype [17] . Similar a rate of decline in GFR of [median (range)] 2.5 (12.9 to Ϫ4.4) ml/min/year while still normotensive, as com-findings have been reported in type 2 diabetic patients with overt nephropathy [18] , and in various types of progression promoter both in type 1 and in type 2 dianondiabetic kidney disease [19] . However, in the present betic patients. Remuzzi and Bertani have suggested that study dealing with normotensive subjects not receiving various types of glomerulosclerosis including diabetic are BP lowering medication, the ACE/ID polymorphism had the consequence of altered glomerular permeability to no significant impact on the deterioration of kidney funcproteins [25] . tion.
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Numerous studies have demonstrated that elevated The present study is the first to demonstrate that short BP is an important progression promoter in diabetic stature and male gender act as independent progression nephropathy [2, 9, 16] . However, this impact is reduced promoter in normotensive type 1 diabetic patients with and sometimes even completely lacking in patients rediabetic nephropathy. The concept that low birth weight, ceiving aggressive antihypertensive treatment leading to known to correlate directly with adult height [20], is normal blood pressure levels [26, 27] . Our study confirms associated with a reduced number of nephrons and thereand extends this observation to include normotensive fore may act as a risk factor for renal disease was origitype 1 diabetic patients not receiving blood pressure nally suggested by Brenner and Chertow [21] . In support lowering agents. of this concept two studies have demonstrated an in-In conclusion, our long-term observational study recreased risk for development of diabetic nephropathy in vealed a rather slow progression of kidney disease in women born with a low birth weight [20] and in men normotensive type 1 diabetic patients with diabetic newith short stature [22] . In contrast, it should be menphropathy. Albuminuria, short stature, and male gender tioned that we were not able to show that low birth act as progression promoters in such patients. weight acted as a progression promoter in diabetic ne- patients receiving antihypertensive treatment (abstract; Jacobsen et al, J Am Soc Nephrol 7:1359 Nephrol 7: , 1996 . Several APPENDIX studies have demonstrated that male gender plays a significant role in the progression of several nondiabetic Abbreviations used in this article are: ACE, angiotensin converting enzyme; ACE/ID, insertion/deletion polymorphism in the angiotensin renal diseases [23] . The exact mechanism of this relationconverting enzyme-gene; BP, blood pressure; BMI, body mass index; ship is not known, but differences in renal hemodynamic, CI, confidence interval; GFR, glomerular filtration rate; HbA 1C , hemoand dietary factors have been proposed [23] . globin A 1C ; PCR, polymerase chain reaction; type 1 diabetes, insulindependent diabetes mellitus.
Albuminuria at baseline and during follow-up was the strongest independent risk factor for loss of filtration REFERENCES power, a finding in agreement with the original demonstration from Watkins et al [24] . Several studies have 1. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR: A prospective study of glomerular filtration rate and confirmed that albuminuria plays an important role as
